No, Clover Biopharmaceutical Co., Ltd. is a China company mainly engaged in biopharmaceuticals. It was listed in Hong Kong on November 5, 221. As of June 18, 222, the listing time was less than one year, and the stock market turnover reached 3.648 million shares. It will not be delisted until it shows a downward trend.

Clover Bio announced the business update and financial performance of the company for the whole year of 222. On February 2th, 223, Clover Bio reached an exclusive commercialization agreement in China on tetravalent seasonal influenza vaccine. On February 14th, 223, Clover Bio-COVID-19 Vaccine Enhancer was launched in China.